Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

被引：0
|
作者：
Campone, Mario
Im, Seock-Ah
Iwata, Hiroji
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Cortes, Javier
De laurentiis, Michele
Arteaga, Carlos L.
Jiang, Zefei
Jonat, Walter
Sellami, Dalila
El-Hashimy, Mona
Le Mouhaer, Sylvie
Sankaran, Banu
Bourdeau, Laurence
Baselga, Jose
机构：
[1] Ctr Rene Gauducheau, Inst Cancerol, Ouest Site, St Herblain, France
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Aichi Canc Ctr, Nagoya, Aichi, Japan
[4] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[6] Inst Jules Bordet, Brussels, Belgium
[7] BC Canc Agcy, Vancouver, BC, Canada
[8] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland
[9] Inst Gustave Roussy, Villejuif, France
[10] Taipei Vet Gen Hosp, Taipei, Taiwan
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[13] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[14] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[16] PLA, Beijing Hosp 307, Beijing, Peoples R China
[17] Univ Hosp Schleswig Holstein, Kiel, Germany
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Novartis Pharmaceut, Florham Pk, NJ USA
[20] Novartis Pharma SAS, Paris, France
[21] Novartis Inst BioMed Res, Cambridge, MA USA
[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-12
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
    De laurentiis, M.
    Mazza, M.
    Mansutti, M.
    Masetti, R.
    Ballatore, Z.
    Torrisi, R.
    Michelotti, A.
    Zambelli, A.
    Ferro, A.
    Generali, D.
    Vici, P.
    Coltelli, L.
    Fabi, A.
    Marchetti, P.
    Ballestrero, A.
    Spazzapan, S.
    Frassoldati, A.
    Sarobba, G.
    Grasso, D.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET). MONALEESA-3.
    Fasching, Peter A.
    Jerusalem, Guy Heinrich Maria
    Pivot, Xavier
    Martin, Miguel
    De laurentiis, Michele
    Blackwell, Kimberly L.
    Esteva, Francisco J.
    Chia, Stephen K. L.
    Germa, Caroline
    Tang, Zhongwen
    Dhuria, Shyeilla V.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
    Sawaki, Masataka
    Muramatsu, Yasuaki
    Togo, Kanae
    Iwata, Hiroji
    CANCER RESEARCH, 2023, 83 (05)
  • [44] PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
    Prat, A.
    Brase, J. C.
    Cheng, Y.
    Nuciforo, P.
    Pare, L.
    Pascual, T.
    Martinez, D.
    Galvan, P.
    Vidal, M.
    Adamo, B.
    Hortobagyi, G.
    Baselga, J.
    Ciruelos, E.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S117 - S117
  • [45] HORMONE RECEPTOR-POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER (ABC): TESTING PATTERNS, PRESCRIBING BEHAVIOR, AND TREATMENT OPTION PERCEPTIONS AMONG US ONCOLOGISTS
    Miller, T.
    Savill, K.
    Jeune-Smith, Y.
    Leon, B.
    Brown, M.
    Klink, A.
    Feinberg, B.
    VALUE IN HEALTH, 2022, 25 (12) : S277 - S277
  • [46] EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) plus /dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
    Gradishar, William John
    Farooki, Azeez
    Giridhar, Karthik
    Moore, Heather
    Johnston, Abigail
    Miller, Michelle Kristine
    Wang, Craig
    Reising, Albert
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [48] Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study
    Blum, J. L.
    Dicristo, C.
    Gordon, D.
    Karuturi, M.
    Oubre, D.
    Jepsen, E.
    Cuevas, J.
    Lakhanpal, S.
    Zhang, Z.
    Drucker, M.
    Wang, Y.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S68 - S69
  • [49] A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Iwata, H.
    Rubovszky, G.
    Loibl, S.
    Ciruelos, E.
    Campone, M.
    Juric, D.
    Rugo, H.
    Mayer, I.
    Conte, P. F.
    Kaufman, B.
    Inoue, K.
    Tesch, H.
    Li, Y-S.
    Mingorance, I. D.
    Ryvo, L.
    Iwase, H.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Andre, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Prat, Aleix
    Chia, Stephen
    Jerusalem, Guy
    Rajappa, Senthil
    Timcheva, Constanta
    Zhukova, Lyudmila
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    De Laurentiis, Michelino
    CANCER RESEARCH, 2021, 81 (04)
12345